

Issued: December 23, 2025.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2025–24015 Filed 12–29–25; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 701–TA–738 and 731–TA–1713–1715 (Final)]

Hexamine (Hexamethylenetetramine) From Germany, India, and Saudi Arabia; Determinations

On the basis of the record¹ developed in the subject investigations, the United States International Trade Commission (“Commission”) determines, pursuant to the Tariff Act of 1930 (“the Act”), that an industry in the United States is materially injured by reason of imports of hexamine from Germany, India, and Saudi Arabia, provided for in subheading 2933.69.50 of the Harmonized Tariff Schedule of the United States, that have been found by the U.S. Department of Commerce (“Commerce”) to be sold in the United States at less than fair value (“LTFV”) and subsidized by the government of India.^{2 3 4}

Background

The Commission instituted these investigations effective September 30, 2024, following receipt of petitions filed with the Commission and Commerce by Bakelite Synthetics (Atlanta, Georgia). The Commission scheduled the final phase of the investigations following notification of preliminary determinations by Commerce that imports of hexamine from China were subsidized within the meaning of section 703(b) of the Act (19 U.S.C. 1671b(b)) and sold at LTFV within the meaning of section 733(b) of the Act (19 U.S.C. 1673b(b)). Notice of the scheduling of the final phase of the Commission’s investigations and of a

public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the **Federal Register** on May 22, 2025 (90 FR 21948 and as revised in 90 FR 31241, July 14, 2025). The Commission conducted its hearing on July 18, 2025. All persons who requested the opportunity were permitted to participate.

The investigation schedules became staggered when Commerce did not align its antidumping and countervailing duty investigations with respect to China with its antidumping duty investigations with respect to Germany, India, and Saudi Arabia, and its countervailing duty investigation with respect to India, and reached earlier final antidumping and countervailing duty determinations with respect to China. On September 3, 2025, the Commission issued final affirmative determinations in its antidumping and countervailing duty investigations of hexamine from China (90 FR 43234, September 8, 2025). Following notification of final determinations by Commerce that imports of hexamine from Germany, India, and Saudi Arabia were being sold at LTFV within the meaning of section 735(a) of the Act (19 U.S.C. 1673d(a)) and that imports of hexamine from India were being subsidized within the meaning of section 703(b) of the Act (19 U.S.C. 1671b(b)), notice of the supplemental scheduling of the final phase of the Commission’s antidumping duty investigations with respect to Germany, India, and Saudi Arabia and its countervailing duty investigation with respect to India was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the **Federal Register** on October 1, 2025 (90 FR 47327).⁵

The Commission made these determinations pursuant to §§ 705(b) and 735(b) of the Act (19 U.S.C. 1671d(b) and 19 U.S.C. 1673d(b)). It completed and filed its determinations in these investigations on December 22, 2025. The views of the Commission are contained in USITC Publication 5693 (December 2025), entitled *Hexamine (Hexamethylenetetramine) from Germany, India, and Saudi Arabia*:

⁵ Due to the lapse in appropriations and ensuing cessation of Commission operations, the Commission tolled its schedule for this proceeding. The schedule was revised in a subsequent notice published in the **Federal Register** on November 20, 2025 (90 FR 52436).

Investigation Nos. 701–TA–738 and 731–TA–1713–1715 (Final).

By order of the Commission.

Issued: December 22, 2025.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2025–23929 Filed 12–29–25; 8:45 am]

BILLING CODE 7020–02–P

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[NASA Document Number: 25–050]

Notice of Intent To Grant an Exclusive, Co-Exclusive or Partially Exclusive Patent License

AGENCY: National Aeronautics and Space Administration (NASA).

ACTION: Notice of intent to grant exclusive, co-exclusive or partially exclusive patent license.

SUMMARY: NASA hereby gives notice of its intent to grant an exclusive, co-exclusive or partially exclusive patent license to practice the inventions described and claimed in the patents and/or patent applications listed in **SUPPLEMENTARY INFORMATION** below.

DATES: The prospective exclusive, co-exclusive or partially exclusive license may be granted unless NASA receives written objections including evidence and argument, no later than January 14, 2026 that establish that the grant of the license would not be consistent with the requirements regarding the licensing of federally owned inventions as set forth in the Bayh-Dole Act and implementing regulations. Competing applications completed and received by NASA no later than January 14, 2026 will also be treated as objections to the grant of the contemplated exclusive, co-exclusive or partially exclusive license. Objections submitted in response to this notice will not be made available to the public for inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act.

ADDRESSES: Written objections relating to the prospective license or requests for further information may be submitted to Agency Counsel for Intellectual Property, NASA Headquarters at Email: hq-patentoffice@mail.nasa.gov. Questions may be directed to Phone: (202) 358–0646.

FOR FURTHER INFORMATION CONTACT: Requests for additional information should be directed to Oliver Sheuer, 202.358.3437, olivia.r.scheuer@nasa.gov.

SUPPLEMENTARY INFORMATION: NASA intends to grant an exclusive, co-

¹ The record is defined in § 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)).

² 90 FR 45728, 45725, 45723, and 45720 (September 23, 2025).

³ Commissioner David S. Johanson determines that an industry in the United States is threatened with material injury by reason of imports of hexamine from Germany, India, and Saudi Arabia that have been found by Commerce to be sold in the United States at LTFV and subsidized by the government of India.

⁴ The Commission also finds that imports subject to Commerce’s affirmative critical circumstances determinations with respect to Germany and India are not likely to undermine seriously the remedial effect of the antidumping duty order on hexamine from Germany or the antidumping duty and countervailing duty orders on hexamine from India.

exclusive, or partially exclusive patent license in the United States to practice the inventions described and claimed in: U.S. Patent No. 9,117,948 title “SELENIUM INTERLAYER FOR HIGH-EFFICIENCY MULTI-JUNCTION SOLAR CELL” and U.S. Patent No. 9,418,844 title “SELENIUM INTERLAYER FOR HIGH-EFFICIENCY MULTI-JUNCTION SOLAR CELL” to Centauri Renewables Corp, having its principal place of business in El Dorado Hills, California. The fields of use may be limited. NASA has not yet made a final determination to grant the requested license and may deny the requested license even if no objections are submitted within the comment period. This notice of intent to grant an exclusive, co-exclusive or partially exclusive patent license is issued in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). The patent rights in these inventions have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective license will comply with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Information about other NASA inventions available for licensing can be found online at <http://technology.nasa.gov>.

Jeffrey Heninger,

Senior Counsel for Intellectual Property,
National Aeronautics and Space
Administration.

[FR Doc. 2025-23928 Filed 12-29-25; 8:45 am]

BILLING CODE 7510-13-P

NUCLEAR REGULATORY COMMISSION

[NRC-2025-1930]

Applications for Amendments to Facility Operating Licenses Involving Proposed No Significant Hazards Consideration Determination and Containing Sensitive Unclassified Non- Safeguards Information and Order Imposing Procedures for Access to Sensitive Unclassified Non-Safeguards Information

AGENCY: Nuclear Regulatory
Commission.

ACTION: License amendment request;
notice of opportunity to comment,
request a hearing, and petition for leave
to intervene; order imposing
procedures.

SUMMARY: The U.S. Nuclear Regulatory
Commission (NRC) received and is
considering approval of three
amendment requests. The amendment

requests are for Braidwood Station,
Units 1 and 2, and Byron Station, Units
1 and 2; Catawba Nuclear Station, Units
1 and 2, and McGuire Nuclear Station,
Units 1 and 2; and Limerick Generating
Station, Units 1 and 2. For each
amendment request, the NRC proposes
to determine that it involves no
significant hazards consideration
(NSHC). Because each amendment
request contains sensitive unclassified
non-safeguards information (SUNSI),
the NRC is issuing an order imposing
procedures to obtain access to SUNSI
for contention preparation by persons
who file a hearing request or petition for
leave to intervene.

DATES: Comments must be received by
January 29, 2026. A request for a hearing
or petitions for leave to intervene must
be filed by March 2, 2026. Any potential
party as defined in section 2.4 of title 10
of the *Code of Federal Regulations* (10
CFR) who believes access to SUNSI is
necessary to respond to this notice must
request document access by January 9,
2026.

ADDRESSES: You may submit comments
by any of the following methods (unless
this document describes a different
method for submitting comments on a
specific subject); however, the NRC
encourages electronic comment
submission through the Federal
rulemaking website.

- *Federal rulemaking website:* Go to <https://www.regulations.gov> and search for Docket ID NRC-2025-1930. Address questions about Docket IDs in *Regulations.gov* to Bridget Curran; telephone: 301-415-1003; email: Bridget.Curran@nrc.gov. For technical questions, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

- *Mail comments to:* Office of Administration, Mail Stop: TWFN-7-A60M, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, ATTN: Program Management, Announcements and Editing Staff.

For additional direction on obtaining information and submitting comments, see “Obtaining Information and Submitting Comments” in the **SUPPLEMENTARY INFORMATION** section of this document.

FOR FURTHER INFORMATION CONTACT:
Karen Zeleznock, Office of Nuclear
Reactor Regulation, U.S. Nuclear
Regulatory Commission, Washington,
DC 20555-0001; telephone: 301-415-
1118; email: Karen.Zeleznock@nrc.gov.

SUPPLEMENTARY INFORMATION:

I. Obtaining Information and Submitting Comments

A. Obtaining Information

Please refer to Docket ID NRC-2025-1930, facility name, unit number(s), docket number(s), application date, and subject when contacting the NRC about the availability of information for this action. You may obtain publicly available information related to this action by any of the following methods:

- *Federal Rulemaking Website:* Go to <https://www.regulations.gov> and search for Docket ID NRC-2025-1930.
- *NRC’s Agencywide Documents Access and Management System (ADAMS):* You may obtain publicly available documents online in the ADAMS Public Documents collection at <https://www.nrc.gov/reading-rm/adams.html>. To begin the search, select “Begin ADAMS Public Search.” For problems with ADAMS, please contact the NRC’s Public Document Room (PDR) reference staff at 1-800-397-4209, at 301-415-4737, or by email to PDR.Resource@nrc.gov. The ADAMS accession number for each document referenced (if it is available in ADAMS) is provided the first time that it is mentioned in this document.

- *NRC’s PDR:* The PDR, where you may examine and order copies of publicly available documents, is open by appointment. To make an appointment to visit the PDR, please send an email to PDR.Resource@nrc.gov or call 1-800-397-4209 or 301-415-4737, between 8 a.m. and 4 p.m. eastern time (ET), Monday through Friday, except Federal holidays.

B. Submitting Comments

The NRC encourages electronic comment submission through the Federal rulemaking website (<https://www.regulations.gov>). Please include Docket ID NRC-2025-1930, facility name, unit number(s), docket number(s), application date, and subject, in your comment submission.

The NRC cautions you not to include identifying or contact information that you do not want to be publicly disclosed in your comment submission. The NRC will post all comment submissions at <https://www.regulations.gov> as well as enter the comment submissions into ADAMS. The NRC does not routinely edit comment submissions to remove identifying or contact information.

If you are requesting or aggregating comments from other persons for submission to the NRC, then you should inform those persons not to include identifying or contact information that they do not want to be publicly